Sustained subconjunctival protein delivery using a thermosetting gel delivery system

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 1, 2010, Pages 55-64

  Rieke, Erin R ^a   Amaral, Juan ^b   Becerra, S Patricia ^b   Lutz, Robert J ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEXA FLUOR 488; ALEXA FLUOR 647; OVALBUMIN; REGEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG RELEASE; FLUORESCENCE MICROSCOPY; GEL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; RETINA; SCLERA;

ANIMALS; CHOROID; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; GELS; MALE; OSMOLAR CONCENTRATION; OVALBUMIN; RATS; RATS, INBRED BN; RETINA; SCLERA; TEMPERATURE;

EID: 77649329002     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0059     Document Type: Article

References (28)

1. Duvvuri, S., Majumdar, S., and Mitra, A.K. Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 3:45-56, 2003.
2. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122:477-485, 2004.
3. Bressler, N.M. Age-related macular degeneration is the leading cause of blindness. JAMA. 291:1900-1901, 2004.
4. Friedman, D.S., O'Colmain, B.J., Muñoz, B., et al.; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122:564-572, 2004.
5. Bressler, N.M.; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfi n: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 119:198-207, 2001.
6. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006.
7. Li, H., Tran, V.V., Hu, Y., et al. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp. Eye Res. 83:824-833, 2006.
8. Ambati, J., Canakis, C.S., Miller, J.W., et al. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 41:1181-1185, 2000.
9. Pitkänen, L., Ranta, V.P., Moilanen, H., et al. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 46:641-646, 2005.
10. Geroski, D.H., and Edelhauser, H.F. Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci. 41:961-964, 2000.
11. Del Amo, E.M., and Urtti, A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today. 13:135-143, 2008.
12. Rathi, R.C., Zentner, G.M., and Jeong, B. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US Patent 6,201,072. March 13, 2001.
13. Huang, X., and Brazel, C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release. 73:121-136, 2001.
14. Zhang, Y., and Chu, C.C. Biodegradable dextran-polylac-tide hydrogel network and its controlled release of albumin. J. Biomed. Mater. Res. 54:1-11, 2001.
15. Kato, A., Kimura, H., Okabe, K., et al. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest. Ophthalmol. Vis. Sci. 45:238-244, 2004.
16. Zentner, G.M., Rathi, R., Shih, C., et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release. 72:203-215, 2001.
17. Bill, A. The aqueous humor drainage mechanism in cynamolgous monkeys with evidence of unconventional drainage. Invest. Ophthalmol. 4:911-919, 1965.
18. Wagner, J.A., Edwards, A., and Schuman, J.S. Characterization of uveoscleral outflow in enucleated porcine eyes perfused under constant pressure. Invest. Ophthalmol. Vis. Sci. 45:3203-3206, 2004.
19. Kim, S.H., Lutz, R.J., Wang, N.S., et al. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 39:244-254, 2007.
20. Amaral, J., Fariss, R.N., Campos, M.M., et al. Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. Invest. Ophthalmol. Vis. Sci. 46:4383-4392, 2005.
21. Mac Gabhann, F., Demetriades, A.M., Deering, T., et al. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann. Biomed. Eng. 35:615-630, 2007.
22. Ambati, J., Gragoudas, E.S., Miller, J.W., et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41:1186-1191, 2000.
23. Demetriades, A.M., Deering, T., Liu, H., et al. Trans-scleral delivery of antiangiogenic proteins. J. Ocul. Pharmacol. Ther. 24:70-79, 2008.
24. Cantrill, H.L., Henry, K., Melroe, N.H., et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology. 96:367-374, 1989.
25. Fu, Y., Ponce, M.L., Thill, M., et al. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest. Ophthalmol. Vis. Sci. 48:5184-5190, 2007.
26. Jaffe, G.J., Yang, C.H., Guo, H., et al. Safety and pharmacokinetics of an intraocular fl uocinolone acetonide sustained delivery device. Invest. Ophthalmol. Vis. Sci. 41:3569-3575, 2000.
27. Pontes de Carvalho, R.A., Krausse, M.L., Murphree, A.L., et al. Delivery from episcleral exoplants. Invest. Ophthalmol. Vis. Sci. 47:4532-4539, 2006.
28. Sakurai, E., Matsuda, Y., Ozeki, H., et al. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. 42:2043-2048, 2001.